menu
    • menu
    [{"orgOrder":0,"company":"CorMedix","sponsor":"ARC Dialysis, LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ ARC Dialysis, LLC","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ ARC Dialysis, LLC"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Suntrust Robinson Humphrey","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Public Offering","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Suntrust Robinson Humphrey","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Suntrust Robinson Humphrey"},{"orgOrder":0,"company":"CorMedix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Undisclosed"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Taurolidine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"New Jersey Economic Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Funding","leadProduct":"Taurolidine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ New Jersey Economic Development Authority","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ New Jersey Economic Development Authority"},{"orgOrder":0,"company":"Undisclosed","sponsor":"CorMedix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Undisclosed \/ CorMedix","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ CorMedix"},{"orgOrder":0,"company":"CorMedix","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Taurolidine","moa":"||TNF-alpha receptor","graph1":"Nephrology","graph2":"Phase IV","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CorMedix \/ RBC Capital Markets","highestDevelopmentStatusID":"11","companyTruncated":"CorMedix \/ RBC Capital Markets"}]

    Find Clinical Drug Pipeline Developments & Deals for Taurolidine

    Menu

    Taurolidine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    CorMedix

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    CorMedix

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Taurolidine,Heparin Sodium

    Therapeutic Area : Immunology

    Study Phase : Approved FDF

    Sponsor : Undisclosed

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    CorMedix Inc. Announces New Commercial Agreement

    Details : Through the agreement, Cordemix will supply DefenCath (taurolidine and heparin) to dialysis clinics for CRBSI in adult patients with kidney failure receiving chronic hemodialysis.

    Product Name : Defencath

    Product Type : Antibiotic

    Upfront Cash : Undisclosed

    September 19, 2024

    Lead Product(s) : Taurolidine,Heparin Sodium

    Therapeutic Area : Immunology

    Highest Development Status : Approved FDF

    Sponsor : Undisclosed

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    CorMedix

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    CorMedix

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Taurolidine,Heparin Sodium

    Therapeutic Area : Immunology

    Study Phase : Approved FDF

    Sponsor : ARC Dialysis, LLC

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC

    Details : Through the agreement, the company will focus on the supply and commercialization of DefenCath (taurolidine and heparin) for the treatment of catheter-related bloodstream infections.

    Product Name : Defencath

    Product Type : Antibiotic

    Upfront Cash : Undisclosed

    August 04, 2024

    Lead Product(s) : Taurolidine,Heparin Sodium

    Therapeutic Area : Immunology

    Highest Development Status : Approved FDF

    Sponsor : ARC Dialysis, LLC

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Undisclosed

    Country arrow
    Pharma Live Expo
    Not Confirmed

    Undisclosed

    Country arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Taurolidine,Heparin Sodium

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved FDF

    Sponsor : CorMedix

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider

    Details : The agreement aims for the supply of DefenCath, a combination of taurolidine, a thiadiazinane antimicrobial and heparin, an anti-coagulant, indicated to reduce catheter-related bloodstream infections.

    Product Name : DefenCath

    Product Type : Antibiotic

    Upfront Cash : Undisclosed

    May 28, 2024

    Lead Product(s) : Taurolidine,Heparin Sodium

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Sponsor : CorMedix

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    CorMedix

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    CorMedix

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Taurolidine,Heparin Sodium

    Therapeutic Area : Nephrology

    Study Phase : Phase IV

    Sponsor : RBC Capital Markets

    Deal Size : $40.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants

    Details : CorMedix intends to use the net proceeds for the commercialization of Taurolock Hep500 (taurolidine), approved to be instilled into catheter-based devices for hemodialysis in order to maintain patency of the vascular access device.

    Product Name : Defencath

    Product Type : Antibiotic

    Upfront Cash : Undisclosed

    June 28, 2023

    Lead Product(s) : Taurolidine,Heparin Sodium

    Therapeutic Area : Nephrology

    Highest Development Status : Phase IV

    Sponsor : RBC Capital Markets

    Deal Size : $40.0 million

    Deal Type : Public Offering

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    CorMedix

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    CorMedix

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Taurolidine,Heparin Sodium

    Therapeutic Area : Immunology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath

    Details : DefenCath is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous cathe...

    Product Name : Defencath

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    June 21, 2023

    Lead Product(s) : Taurolidine,Heparin Sodium

    Therapeutic Area : Immunology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    CorMedix

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    CorMedix

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Taurolidine,Heparin Sodium

    Therapeutic Area : Immunology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    CorMedix Inc. Announces Resubmission of New Drug Application for DefenCath

    Details : DefenCath™ is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous ca...

    Product Name : Defencath

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    May 16, 2023

    Lead Product(s) : Taurolidine,Heparin Sodium

    Therapeutic Area : Immunology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    CorMedix

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    CorMedix

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Taurolidine,Heparin Sodium

    Therapeutic Area : Immunology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    CorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCath

    Details : DefenCath™ is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous ca...

    Product Name : Defencath

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    January 05, 2023

    Lead Product(s) : Taurolidine,Heparin Sodium

    Therapeutic Area : Immunology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    CorMedix

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    CorMedix

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Taurolidine,Citric Acid,Heparin Sodium

    Therapeutic Area : Immunology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    CorMedix Inc. Announces Regulatory and Manufacturing Updates

    Details : Defencath is available in Europe and other territories under the brand name Neutrolin. It is used for catheter-related bloodstream infections in patients with end-stage renal disease receiving hemodialysis through a central venous catheter.

    Product Name : Defencath

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    August 08, 2022

    Lead Product(s) : Taurolidine,Citric Acid,Heparin Sodium

    Therapeutic Area : Immunology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    CorMedix

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    CorMedix

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Taurolidine,Citric Acid,Heparin Sodium

    Therapeutic Area : Immunology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Cormedix Inc. Announces Resubmission Of New Drug Application For DefenCath

    Details : DefenCath is being developed as a catheter lock solution with an initial indication of use for the reduction of catheter-related bloodstream infections (CRBSIs) in patients with renal failure who are receiving chronic hemodialysis via a central venous ca...

    Product Name : Defencath

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    February 28, 2022

    Lead Product(s) : Taurolidine,Citric Acid,Heparin Sodium

    Therapeutic Area : Immunology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    CorMedix

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    CorMedix

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Taurolidine,Citric Acid,Heparin Sodium

    Therapeutic Area : Immunology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    CorMedix Inc. Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Defencath

    Details : U.S. FDA has accepted for filing the Company’s submitted New Drug Application (NDA) for Defencath™, its product candidate to be used as a catheter lock solution in hemodialysis patients for the prevention of catheter related blood stream infections (...

    Product Name : Defencath

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    August 31, 2020

    Lead Product(s) : Taurolidine,Citric Acid,Heparin Sodium

    Therapeutic Area : Immunology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth